

Ivan Budnik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5579262/publications.pdf>

Version: 2024-02-01

45
papers

660
citations

759233

12
h-index

610901

24
g-index

45
all docs

45
docs citations

45
times ranked

923
citing authors

#	ARTICLE	IF	CITATIONS
1	Pediatric severe factor XI deficiency: A multicenter study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29545.	1.5	2
2	Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study. <i>Blood Cells, Molecules, and Diseases</i> , 2022, 95, 102663.	1.4	3
3	Thromboelastometry assessment of the effects of fibrinogen, activated prothrombin complex concentrate, and tranexamic acid on clot formation and fibrinolysis in a model of trauma-induced coagulopathy. <i>European Journal of Trauma and Emergency Surgery</i> , 2021, 47, 1057-1063.	1.7	2
4	The potential role of emicizumab prophylaxis in severe von Willebrand disease. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102530.	1.4	9
5	Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction. <i>Biomolecules</i> , 2021, 11, 358.	4.0	5
6	Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data. <i>Haemophilia</i> , 2021, 27, 253-260.	2.1	23
7	Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring. <i>Haemophilia</i> , 2021, 27, 383-391.	2.1	34
8	Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9074.	4.1	8
9	Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 4303.	2.4	15
10	Urinary biomarkers of latent inflammation and fibrosis in children with vesicoureteral reflux. <i>International Urology and Nephrology</i> , 2020, 52, 603-610.	1.4	10
11	The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia. <i>Experimental and Molecular Pathology</i> , 2020, 116, 104524.	2.1	4
12	Emicizumab treatment and monitoring in a paediatric cohort: real-world data. <i>British Journal of Haematology</i> , 2020, 191, 282-290.	2.5	57
13	In-vitro assessment of the effects of fibrinogen, recombinant factor VIIa and factor XIII on trauma-induced coagulopathy. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 253-257.	1.0	3
14	Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors—a single-center cohort. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27886.	1.5	65
15	Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1927-1932.	3.4	7
16	Activated protein C induces suppression and regression of choroidal neovascularization—A murine model. <i>Experimental Eye Research</i> , 2019, 186, 107695.	2.6	6
17	Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients. <i>Thrombosis and Haemostasis</i> , 2019, 119, 117-127.	3.4	9
18	Epiretinal membrane following pars plana vitrectomy for rhegmatogenous retinal detachment repair. <i>International Journal of Ophthalmology</i> , 2019, 12, 1872-1877.	1.1	10

#	ARTICLE	IF	CITATIONS
19	Role of heterotrimeric G proteins in platelet activation and clot formation in platelets treated with integrin α IIb β 3 inhibitor. <i>Platelets</i> , 2018, 29, 265-269.	2.3	3
20	Hypoxic renal injury in newborns with abdominal compartment syndrome (clinical and experimental) <i>Tj ETQqO O O rgBT /Overlock 10 Tf 5</i>	2.3	8
21	Immune Factors in Deep Vein Thrombosis Initiation. <i>Trends in Immunology</i> , 2018, 39, 610-623.	6.8	128
22	Correction of coagulopathy in thrombocytopenia and Glanzmann thrombasthenia models by fibrinogen and factor XIII as assessed by thromboelastometry. <i>Pathophysiology</i> , 2018, 25, 347-351.	2.2	3
23	Role of interleukin-10 and interleukin-24 in the pathogenesis of Φ '-cell chronic lymphocytic leukemia. <i>Nauchno-prakticheskii Zhurnal "Patogenez"</i> , 2018, , 56-61.	0.2	0
24	Improving clot formation with a combination of fibrinogen concentrate and activated prothrombin complex concentrate in a model of severe thrombocytopenia. <i>Nauchno-prakticheskii Zhurnal "Patogenez"</i> , 2018, , 23-29.	0.2	0
25	Activated Protein C Induces Stabilization of the Outer Retinal Barrier and Inhibits Laser Induced Choroidal Neovascularization in a Murine Model. <i>Blood</i> , 2018, 132, 73-73.	1.4	0
26	Effect of Subretinal Fluid Drainage Using Perfluorocarbon During Retinal Detachment Repair on Postoperative Metamorphopsia. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018, 49, e263-e270.	0.7	3
27	Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 1-7.	1.4	30
28	Correlation between Interleukin-6 and Thrombin-Antithrombin III Complex Levels in Retinal Diseases. <i>Current Eye Research</i> , 2017, 42, 1269-1272.	1.5	6
29	Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 66, 1-5.	1.4	8
30	Model of trauma-induced coagulopathy including hemodilution, fibrinolysis, acidosis, and hypothermia. <i>Journal of Trauma and Acute Care Surgery</i> , 2017, 82, 287-292.	2.1	41
31	EXPERIMENTAL AND CLINICAL RATIONAL FOR TERAHERTZ THERAPY AT THE FREQUENCY OF MOLECULAR OXYGEN AND NITROGEN OXIDE ABSORPTION AND EMISSION IN DIFFERENT PATHOLOGIES. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2017, 72, 365-374.	0.6	3
32	Reflux nephropathy in children: early diagnosis and monitoring. <i>Urologiia</i> , 2017, 4_2017, 107-112.	0.2	0
33	Intra-abdominal Hypertension Syndrome in Children. <i>Novosti Khirurgii</i> , 2017, 25, 621-631.	0.2	0
34	Effects of fibrinogen concentrate, factor XIII, and thrombin-activatable fibrinolysis inhibitor on clot firmness and fibrinolytic resistance in the model of hyperfibrinolysis. <i>Patologicheskaiia Fiziologiia i Eksperimental'naia Terapiia</i> , 2017, , 44-50.	0.1	0
35	Role of G protein signaling in the formation of the fibrin(ogen)-integrin α IIb β 3-actin cytoskeleton complex in platelets. <i>Platelets</i> , 2016, 27, 563-575.	2.3	5
36	Urinary cytokines as markers of latent inflammation in children with chronic pyelonephritis and anorectal malformations. <i>Journal of Pediatric Urology</i> , 2016, 12, 153.e1-153.e6.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin-activatable fibrinolysis inhibitor. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 521-529.	1.3	9
38	The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. <i>Thrombosis Research</i> , 2015, 136, 465-473.	1.7	33
39	Synergistic effect of signaling from receptors of soluble platelet agonists and outside-in signaling in formation of a stable fibrinogen-integrin $\alpha\text{IIb}\beta\text{3}$ -actin cytoskeleton complex. <i>Thrombosis Research</i> , 2015, 135, 114-120.	1.7	7
40	In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. <i>Blood Transfusion</i> , 2014, 12, 78-84.	0.4	18
41	Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 729-733.	1.0	9
42	The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 370-378.	1.0	17
43	The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia. <i>Platelets</i> , 2012, 23, 604-610.	2.3	12
44	Risk assessment of simple phacoemulsification in patients on combined anticoagulant and antiplatelet therapy. <i>Journal of Cataract and Refractive Surgery</i> , 2011, 37, 1434-1438.	1.5	23
45	Differential Roles of Fibrinogen and von Willebrand Factor on Clot Formation and Platelet Adhesion in Reconstituted and Immune Thrombocytopenia. <i>Anesthesia and Analgesia</i> , 2011, 112, 1034-1040.	2.2	15